The First Affiliated Hospital of Sun Yat-sen University
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China26 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 3 | 2026-09-17 | NCT06340568 | |
| TEER In dynaMic sEvere Functional Mitral Regurgitation (TIMER) | Mitral Regurgitation Functional | Not yet recruiting | Not applicable | 2026-09-04 | NCT07197021 | |
| A Simulated Case Study of a Peritoneal Dialysis-Specialized Large Language Model Assisting Doctors in Improving Decision-Making in Peritoneal Dialysis Management | Large Language Models; Peritoneal Dialysis (PD) | Enrolling by invitation | Not applicable | 2026-07-24 | NCT07724327 | |
| ABTECT - Maintenance | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Active, not recruiting | Phase 3 | 2026-07-07 | NCT05535946 | |
| PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer | Gastric or Esophagogastric Junction Adenocarcinoma | Active, not recruiting | Phase 3 | 2026-07-07 | NCT05180734 | |
| New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease | Not yet recruiting | Phase 3 | 2026-06-09 | NCT07635953 | |
| Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | Moderately to Severely Active Ulcerative Colitis | Active, not recruiting | Phase 3 | 2026-05-22 | NCT03221036 | |
| A Study of SHR-2173 in Participants With Primary IgA Nephropathy | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Recruiting | Phase 2 | 2026-05-13 | NCT07354932 | |
| Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss | Ear Diseases, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, hearing disorder, hearing loss disorder, nervous system disorder, otorhinolaryngologic disease, sudden sensorineural hearing loss | Not yet recruiting | Phase 1 / Phase 2 | 2026-03-25 | NCT07404709 | |
| Safety and Efficacy of Small Extracellular Vesicles Nebulizer in Patients With Allergic Rhinitis Complicated With Asthma | Hypersensitivity, Immediate, Respiratory Hypersensitivity, Rhinitis, Allergic, asthma, bronchial disorder, immune system disorder, lung disorder, nasal disorder, obstructive lung disease, otorhinolaryngologic disease, respiratory system disorder, rhinitis | Not yet recruiting | Not applicable | 2026-03-06 | NCT07453771 | |
| Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 3 | 2026-02-06 | NCT06127407 | |
| A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 3 | 2025-09-05 | NCT05459844 | |
| Efficacy and Safety of SR1375 in Adult Patients With CAP | Community-Acquired Infections, Community-Acquired Pneumonia, Infections, pneumonia, respiratory system disorder, respiratory tract infectious disorder | Recruiting | Phase 2 | 2025-07-09 | NCT06577558 | |
| Extent of Lymph Node Dissection for Advanced Right-Sided Colon Cance | Advanced Right-sided Colon Cancer; the Extent of Lymph Node Dissection | Not yet recruiting | Not applicable | 2025-05-23 | NCT06986538 | |
| New Triple Therapy in Newly Diagnosed Type 2 Diabetes | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease | Not yet recruiting | Phase 3 | 2025-04-27 | NCT06946628 | |
| A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Active, not recruiting | Phase 3 | 2025-04-13 | NCT04974398 | |
| CAP-TEER: CerebrAl Protection During Transcatheter Edge-to-edge Repair | cardiovascular disorder, heart disorder, heart valve disorder, mitral valve insufficiency | Not yet recruiting | Not applicable | 2025-02-07 | NCT06814210 | |
| Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2025-01-09 | NCT04615143 | |
| EArly Effect of Glucocorticoid on Incidence of Persistent Left BundlE Branch Block (LBBB) Post-TAVR (EAGLE-TAVR Trial) | Arrhythmias, Cardiac, Cardiac Conduction System Disease, Left Bundle-Branch Block, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrioventricular dissociation, cardiovascular disorder, heart disorder, progressive familial heart block, type 1A | Not yet recruiting | Phase 4 | 2025-01-07 | NCT06762145 | |
| SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma. | Unresectable Hepatocellular Carcinoma (HCC) | Not yet recruiting | Phase 2 / Phase 3 | 2024-12-18 | NCT06739317 | |
| High Quality Evidence of Guangzhou Lupus Nephritis Cohort (HOPE Cohort) | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Urogenital Diseases, autoimmune disease, chronic renal failure syndrome, connective tissue disorder, glomerulonephritis, immune system disorder, kidney disorder, kidney failure, lupus nephritis, nephritis, systemic lupus erythematosus, urinary system disorder | Recruiting | Not stated | 2024-11-12 | NCT06682507 | |
| Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, biliary tract cancer, biliary tract disorder, neoplasm | Not yet recruiting | Phase 2 / Phase 3 | 2024-10-29 | NCT06662877 | |
| To Evaluate Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection | hypogonadotropic hypogonadism 7 with or without anosmia | Not yet recruiting | Phase 3 | 2024-08-20 | NCT06561594 | |
| A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 3 | 2023-08-14 | NCT05990127 | |
| SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH) | Advanced Hepatocellular Carcinoma | Not yet recruiting | Phase 3 | 2023-02-08 | NCT05718232 |